The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are:
* Is this intervention effective in improving mental health? * Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.
Value above a cut-off of the DASS-21 subscales (depression > 10, anxiety > 6, and stress > 10)
Sufficient cognition and language ability (clinical rating)
Sufficient therapy motivation (clinical rating)
Behavioral disorders (e.g., high irritability or apathy in clinical rating)
Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability)
Simultaneous psychotherapy or neuropsychological therapy